<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175225</url>
  </required_header>
  <id_info>
    <org_study_id>2012P000005</org_study_id>
    <secondary_id>U01NS074425</secondary_id>
    <nct_id>NCT02175225</nct_id>
  </id_info>
  <brief_title>Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial</brief_title>
  <official_title>Study of Deferoxamine Mesylate in Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry Ford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Joseph's Hospital and Medical Center, Phoenix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale New Haven Health System Center for Healthcare Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital de l'Enfant-Jesus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Sinai Hospital, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate,
      improves the outcome of patients with brain hemorrhage.

      The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of
      sufficient promise to improve outcome before pursuing a larger clinical trial to examine its
      effectiveness as a treatment for intracerebral hemorrhage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, double-blind, randomized, placebo-controlled, phase-II
      clinical trial.

      Subjects will be randomized to either deferoxamine mesylate (DFO) at 32 mg/kg/day (up to a
      maximum daily dose of 6000 mg/day), or saline placebo, given by IV infusion for 3 consecutive
      days.

      Treatment will be initiated within 24 hours after ICH symptom onset. Randomization will
      control baseline imbalances associated with baseline ICH score, ICH onset-to-treatment time
      (OTT), ICH volume, baseline NIHSS score, and warfarin use.

      All subjects will be followed for 6 months and will receive standard of care therapy while
      participating in the study.

      Throughout the study, we will continue to assess the safety of DFO. At the conclusion of the
      study, the proportion of DFO-treated subjects with a good clinical outcome at 3 months
      (defined as modified Rankin Scale (mRS) score of 0-2) will be compared to the placebo
      proportion in a futility analysis to determine if it is futile to move DFO forward to Phase
      III efficacy evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Modified Rankin Scale (mRS) Score 0-2</measure>
    <time_frame>3 months</time_frame>
    <description>The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>All adverse events (serious and non-serious) will be assessed until day-7 or discharge (whichever is earlier), and serious adverse events (SAEs) until day-90.
Safety endpoints will include all DFO-related adverse events until day-7 or discharge (whichever is earlier), and SAEs through day-90.
Mortality (all cause and ICH-related) will be assessed through day 180.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with mRS score 0-3</measure>
    <time_frame>3 months</time_frame>
    <description>Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 90 days.
Although mRS 0-3 is less favorable than the primary outcome of mRS 0-2, it would still be a desirable effect in patients with ICH given that no treatments exist to reduce disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Modified Rankin Scale (mRS) Score 0-2</measure>
    <time_frame>6 months</time_frame>
    <description>Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Modified Rankin Scale (mRS) Score 0-3</measure>
    <time_frame>6 months</time_frame>
    <description>Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with good outcome in the early vs. delayed treatment time windows</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>Analyses will be expanded to include an interaction between treatment and OTT window and the magnitude of the treatment effect, and corresponding confidence interval, will be estimated for each time window (&lt;12 hours vs. &gt;/= 12 hours) in order to explore the presence of a differential treatment effect in the OTT windows.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ordinal distribution of scores on mRS</measure>
    <time_frame>90 and 180 days</time_frame>
    <description>The overall ordinal distribution of scores on mRS at 3 and 6 months in DFO- and placebo-treated subjects will be determined.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Deferoxamine Mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferoxamine Mesylate</intervention_name>
    <arm_group_label>Deferoxamine Mesylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Deferoxamine Mesylate)</intervention_name>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 and ≤ 80 years

          -  The diagnosis of ICH is confirmed by brain CT scan

          -  NIHSS score ≥6 and GCS &gt;6 upon presentation

          -  The first dose of the study drug is expected to be administered within 24h of ICH
             symptom onset

          -  Functional independence prior to ICH, defined as pre-ICH mRS ≤1

          -  Signed and dated informed consent is obtained.

        Exclusion Criteria:

          -  Previous chelation therapy or known hypersensitivity to DFO products

          -  Known severe iron deficiency anemia (defined as hemoglobin concentration &lt; 7g/dL or
             requiring blood transfusions)

          -  Abnormal renal function, defined as serum creatinine &gt;2 mg/dL

          -  Planned surgical evacuation of ICH prior to administration of study drug (placement of
             a catheter for ventricular drainage is not a contraindication to enrollment)

          -  SUSPECTED secondary ICH related to tumour, ruptured aneurysm or arteriovenous
             malformation, hemorrhagic transformation of an ischemic infarct, or venous sinus
             thrombosis

          -  Infratentorial hemorrhage

          -  Irreversibly impaired brainstem function (bilateral fixed and dilated pupils and
             extensor motor posturing)

          -  Complete unconsciousness, defined as a score of 3 on item 1a of the NIHSS (Responds
             only with reflex motor or autonomic effects or totally unresponsive, and flaccid)

          -  Pre-existing disability, defined as pre-ICH mRS ≥2

          -  Coagulopathy - defined as elevated aPTT or INR &gt;1.3 upon presentation; concurrent use
             of direct thrombin inhibitors (such as dabigatran), direct factor Xa inhibitors (such
             as rivaroxaban or apixaban), or low-molecular-weight heparin

          -  Patients with confirmed aspiration, pneumonia, or evident bilateral pulmonary
             infiltrates on chest x-ray or CT scan prior to enrollment

          -  Patients with significant respiratory disease such as chronic obstructive pulmonary
             disease, pulmonary fibrosis, or any use (chronic or intermittent) of inhaled O2 at
             home

          -  FiO2 &gt;0.35 (&gt;4 L/min) prior to enrollment

          -  Sepsis (present source of infection ± lactic acidosis); Systemic Inflammatory Response
             Syndrome (Temp &gt;100.4F or &lt;96.8F; Heart rate &gt;90; Respiratory rate &gt;20 or PaCo2 &lt;32
             mmHg; WBC &gt;12, &lt;4, or bands &gt;10%); or shock (SBP &lt;90 mmHg) at presentation

          -  The presence of 4 or more of the following risk modifiers for ARDS prior to
             enrollment:

               1. Tachypnea (respiratory rate &gt;30)

               2. SpO2 &lt;95%

               3. Obesity (BMI &gt;30)

               4. Acidosis (pH &lt;7.35)

               5. Hypoalbuminemia (albumin &lt;3.5 g/dL)

               6. Concurrent use of chemotherapy

          -  Taking iron supplements containing ≥ 325 mg of ferrous iron, or prochlorperazine

          -  Patients with heart failure taking &gt; 500 mg of vitamin C daily

          -  Known severe hearing loss

          -  Known pregnancy, or positive pregnancy test, or breastfeeding

          -  Positive drug screen for cocaine upon presentation

          -  Patients known or suspected of not being able to comply with the study protocol due to
             alcoholism, drug dependency, noncompliance, living in another state or any other cause

          -  Any condition which, in the judgement of the investigator, might increase the risk to
             the patient

          -  Life expectancy of less than 90 days due to co-morbid conditions

          -  Concurrent participation in another research protocol for investigation of another
             experimental therapy

          -  Indication that a new DNR or Comfort Measures Only (CMO) order will be implemented
             within the first 72 hours of hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy Selim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital / Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RUSH University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Medical Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Hospital - University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta - Mackenzie Health Sciences Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Québec - Hôpital de l'Enfant-Jésus</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yeatts SD, Palesch YY, Moy CS, Selim M. High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocrit Care. 2013 Oct;19(2):257-66. doi: 10.1007/s12028-013-9861-y.</citation>
    <PMID>23943316</PMID>
  </reference>
  <reference>
    <citation>Selim M, Yeatts S, Goldstein JN, Gomes J, Greenberg S, Morgenstern LB, Schlaug G, Torbey M, Waldman B, Xi G, Palesch Y; Deferoxamine Mesylate in Intracerebral Hemorrhage Investigators. Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke. 2011 Nov;42(11):3067-74. doi: 10.1161/STROKEAHA.111.617589. Epub 2011 Aug 25.</citation>
    <PMID>21868742</PMID>
  </reference>
  <reference>
    <citation>Selim M. Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke. 2009 Mar;40(3 Suppl):S90-1. doi: 10.1161/STROKEAHA.108.533125. Epub 2008 Dec 8. Review.</citation>
    <PMID>19064798</PMID>
  </reference>
  <reference>
    <citation>Hatakeyama T, Okauchi M, Hua Y, Keep RF, Xi G. Deferoxamine reduces neuronal death and hematoma lysis after intracerebral hemorrhage in aged rats. Transl Stroke Res. 2013 Oct;4(5):546-53. doi: 10.1007/s12975-013-0270-5.</citation>
    <PMID>24187595</PMID>
  </reference>
  <reference>
    <citation>Xie Q, Gu Y, Hua Y, Liu W, Keep RF, Xi G. Deferoxamine attenuates white matter injury in a piglet intracerebral hemorrhage model. Stroke. 2014 Jan;45(1):290-2. doi: 10.1161/STROKEAHA.113.003033. Epub 2013 Oct 30.</citation>
    <PMID>24172580</PMID>
  </reference>
  <reference>
    <citation>Okauchi M, Hua Y, Keep RF, Morgenstern LB, Schallert T, Xi G. Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. Stroke. 2010 Feb;41(2):375-82. doi: 10.1161/STROKEAHA.109.569830. Epub 2009 Dec 31.</citation>
    <PMID>20044521</PMID>
  </reference>
  <reference>
    <citation>Sonni S, Lioutas VA, Selim MH. New avenues for treatment of intracranial hemorrhage. Curr Treat Options Cardiovasc Med. 2014 Jan;16(1):277. doi: 10.1007/s11936-013-0277-y.</citation>
    <PMID>24366522</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>January 7, 2018</last_update_submitted>
  <last_update_submitted_qc>January 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Magdy Selim</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Brain hemorrhage</keyword>
  <keyword>Cerebral hemorrhage</keyword>
  <keyword>Bleeding in the brain</keyword>
  <keyword>Deferoxamine</keyword>
  <keyword>iDEF trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

